DGIdb - CYTARABINE Drug Record

CYTARABINE chembl:CHEMBL803 ApprovedAntineoplasticImmunotherapy

Alternate Names:

ARABINOSYL CYTOSINE
U-19920
DEPOCYTE
DEPOCYT
TARABINE PFS
ARA-CYTIDINE
NSC-287459
CYTARABINE
ALEXAN 100
CYTOSAR-U
ALEXAN
CYTOSAR
CYTOSINE-BETA-D-ARABINOFURANOSIDE
CITARABINA
CYTOSINE ARABINOSIDE
CYTOSAR®
CYTARABINUM
1-BETA-D-ARABINOFURANOSYLCYTOSINE
CYTOSINE-1-BETA-D-ARABINOFURANOSIDE
4-AMINO-1-BETA-D-ARABINOFURANOSYL-2(1H)-PYRIMIDINONE
CYTOSINE-Β-D-ARABINOFURANOSIDE
DEPOCYTE®
chemidplus:147-94-4
pubchem.compound:6253
rxcui:3041
drugbank:00987
chembl:CHEMBL803

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Class	antineoplastic agents
Year of Approval	1969

(7 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Cao X et al., 2013, RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients., Pharmacogenomics
Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
Stone et al., 2017, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation., N. Engl. J. Med.
Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.
Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
Galmarini et al., 2002, Potential mechanisms of resistance to cytarabine in AML patients., Leuk. Res.
Serdjebi C et al., 2014, Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?, Pharmacogenet Genomics
Carpi FM et al., 2013, CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population., Pharmacogenomics
Baker JA et al., 2013, Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase., Drug Metab Dispos
Ciccolini J et al., 2012, CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations., Pharmacogenomics
Abraham A et al., 2012, Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia., Pharmacogenomics
Parmar S et al., 2011, Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells., Pharmacogenomics
Caronia D et al., 2011, A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome., Clin Cancer Res
Mahlknecht U et al., 2009, SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival., Leukemia
Ribelles N et al., 2008, A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression., Curr Drug Metab
Cheong HS et al., 2014, NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia., Pharmacogenet Genomics
Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.
He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE
Krynetskaia et al., 2009, Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage., Mol. Cancer Ther.
Angeli et al., 2006, Anti-clastogenic effect of beta-glucan extracted from barley towards chemically induced DNA damage in rodent cells., Hum Exp Toxicol
Miura et al., 2004, DNA polymerases as targets of anticancer nucleosides., Curr Drug Targets
Ustun et al., 2009, Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V., Leuk. Res.
Adams et al., 1985, Altered mouse bone marrow glutathione and glutathione transferase levels in response to cytotoxins., Cancer Res.
Drenberg CD et al., 2016, ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression., Clin Transl Sci
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Shi JY et al., 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients., Pharmacogenetics
Gaidzik et al., 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group., J. Clin. Oncol.
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

CYTARABINE CDA

Interaction Score: 2.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12008078 25003625 23651026 23230131 22379997 22304580 21521023 21325291 19458626 18473752

Sources:
NCI PharmGKB
CYTARABINE MED12L

Interaction Score: 2.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
CYTARABINE GATA1

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type megakaryocytic leukemia

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
23874683

Sources:
JAX-CKB
CYTARABINE SULT2B1

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
CYTARABINE NT5C3A

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25000516

Sources:
PharmGKB
CYTARABINE IKZF1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30044693

Sources:
CIViC
CYTARABINE DROSHA

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24614921

Sources:
PharmGKB
CYTARABINE SLC22A12

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
CYTARABINE WT1

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18591546

Sources:
CIViC
CYTARABINE RRM2B

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24024897

Sources:
PharmGKB
CYTARABINE NT5C2

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYTARABINE BMP7

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
CYTARABINE POLD1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CYTARABINE LINC00251

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
CYTARABINE POLE

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
CYTARABINE DOK5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
CYTARABINE DCK

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15564883

Sources:
PharmGKB
CYTARABINE RRM2

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24024897

Sources:
PharmGKB
CYTARABINE GATA3

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
CYTARABINE P2RY12

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
CYTARABINE POLA1

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CYTARABINE RRM1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24024897

Sources:
PharmGKB
CYTARABINE NCOA3

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYTARABINE CYP2E1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
CYTARABINE TYMSOS

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYTARABINE ABCC4

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26842729

Sources:
PharmGKB
CYTARABINE HSPA4

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12530536

Sources:
NCI
CYTARABINE FLT3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cytarabine + Daunorubicin + Midostaurin

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
27626069 28644114 25818407 22627678

Sources:
JAX-CKB
CYTARABINE SLCO1B1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398 22584460

Sources:
PharmGKB
CYTARABINE RUNX1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21343560

Sources:
CIViC
CYTARABINE GSTP1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3978635

Sources:
NCI
CYTARABINE KMT2A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute lymphocytic leukemia

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27443263

Sources:
JAX-CKB
CYTARABINE KIT

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dasatinib + Cytarabine

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
18986703

Sources:
JAX-CKB
CYTARABINE POLB

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-351, cytarabine + daunorubicin

Novel drug target Established target

Trial Name cytarabine liposome injection,DepoCyt

PMIDs:
19372559 16866189 15011952

Sources:
TdgClinicalTrial TEND
CYTARABINE TYMS

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYTARABINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB
CYTARABINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CYTARABINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CYTARABINE CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CYTARABINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CYTARABINE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
CYTARABINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CYTARABINE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CYTARABINE
- Version: 01-August-2011
Alternate Names:

CYTARABINE Primary Drug Name

Drug Info:

Year of Approval 1969

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: CYTARABINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: CYTARABINE

Version: 14-September-2017

Alternate Names:

C408 NCI drug code

Drug Info:

Publications:

Galmarini et al., 2002, Potential mechanisms of resistance to cytarabine in AML patients., Leuk. Res.

Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.

NCI: 1-BETA-D-ARABINOFURANOSYLCYTOSINE
- Version: 14-September-2017
Alternate Names:

C408 NCI drug code

Drug Info:

Publications:

Adams et al., 1985, Altered mouse bone marrow glutathione and glutathione transferase levels in response to cytotoxins., Cancer Res.
DTC: CYTARABINE
- Version: 02-September-2020
Alternate Names:

CHEMBL803 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: cytarabine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

Drenberg CD et al., 2016, ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression., Clin Transl Sci

Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

JAX-CKB: Cytarabine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE

Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia

Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.

CIViC: CYTARABINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.

Gaidzik et al., 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group., J. Clin. Oncol.

Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

TTD: Cytarabine
- Version: 2020.06.01
Alternate Names:

D07XSN TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL803
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL803
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	megakaryocytic leukemia
Response Type	decreased response
Approval Status	Preclinical - Cell culture

Mechanism of Interaction	DNA polymerase (alpha/delta/epsilon) inhibitor
Direct Interaction	yes

combination therapy	Cytarabine + Daunorubicin + Midostaurin
Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive

Indication/Tumor Type	acute lymphocytic leukemia
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

combination therapy	Dasatinib + Cytarabine
Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive

Trial Name	CPX-351, cytarabine + daunorubicin
Novel drug target	Established target
Trial Name	cytarabine liposome injection,DepoCyt

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

CYTARABINE Drug Record

CYTARABINE chembl:CHEMBL803 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12008078 25003625 23651026 23230131 22379997 22304580 21521023 21325291 19458626 18473752

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type megakaryocytic leukemia Response Type decreased response Approval Status Preclinical - Cell culture

PMIDs: 23874683

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25000516

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30044693

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24614921

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18591546

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24024897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15564883

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24024897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24141364

Interaction Types & Directionality:

n/a

PMIDs:
12008078 25003625 23651026 23230131 22379997 22304580 21521023 21325291 19458626 18473752

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type megakaryocytic leukemia

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
23874683

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25000516

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30044693

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24614921

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18591546

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24024897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15564883

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24024897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24141364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA polymerase (alpha/delta/epsilon) inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
24024897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a